ArticleCureus2022
Coverage of Coronavirus Disease-2019 (COVID-19) Booster Dose (Precautionary) in the Adult Population: An Online Survey.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.Scientific reports · 2023Trial
- PCR Test Positivity and Viral Loads during Three SARS-CoV-2 Viral Waves in Mumbai, India.Biomedicines · 2023Article
- COVID-19 Booster Dose Coverage and Hesitancy among Older Adults in an Urban Slum and Resettlement Colony in Delhi, India.Vaccines · 2023Article
- Review
- Facilitators and barriers to the uptake of COVID-19 vaccine precaution dose among adult population: qualitative analysis across six different states of India.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The coronavirus disease-2019 (COVID-19) pandemic devastated public health worldwide, including India. COVID-19 vaccines and their boosters are life-saving developments that have helped prevent and control the spread of COVID-19. We conducted this study to assess the coverage of the booster dose in an Indian population (the third dose of the COVID-19 vaccine in India is referred to as the booster or precautionary dose), record the reasons for not taking the booster dose, and determine the effectiveness of the booster. The levels of adherence to COVID-19 precautionary behavior was also assessed. Methods We conducted a descriptive, cross-sectional study using convenient sampling via an online survey of 550 respondents older than 18 in the second quarter of 2022. The respondents were distributed among 18 states and union territories in India. The data were analyzed as simple proportions and percentages. Results Of the 550 respondents, 152 (27.6%) received the booster dose, indicating low coverage. A small percentage of respondents (7.2%) reported suffering from COVID-19 following the booster, of whom 91% were medical professionals. The most common reported reason for not taking the vaccine was that the respondents were not yet due for their dose (48.1%). The time between the second dose of the COVID-19 vaccine and the booster had no impact on infection rates. Men were less likely to adhere to COVID-19 precautionary behavior than women, despite similar vaccination rates. Conclusion The COVID-19 vaccine booster had a low acceptance in our study population, with roughly one-quarter of the population receiving the booster. The booster dose has been influential in the prevention of COVID-19. Most respondents followed behavioral safety measures despite the decline of active cases of COVID-19 in India following the Omicron wave. Our results indicate a need to strengthen public strategies to affect behavioral changes, such as improving India's Behavior Change Communication program to ensure adequate booster dose coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.